Pura Vida Investments LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Pura Vida Investments LLC
CRD #166703
SEC #801-80547
CIK #0001590144
AUM 91.5 M (2026-03-30)
Employees 2 (50% Investors, 0% Brokers)
Fees
Minimum
Phone929-733-7678
Address545 W 25th Street
New York, NY 10001
Source [IAPD] [EDGAR] [Website]
Total AUM ($M)
18001440108072036002010201520212027
Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure]
Item 5. Fees and Compensation

The Adviser charges certain of the Clients an investment management fee (the “Management Fee”) based
on either the value of the Client’s assets under management or, for certain investments, the lower of the
investment’s cost or market value. The Management Fee for Pura Vida Funds is generally payable to the
Adviser monthly in advance and is at an annual rate of up to 2% of the value of each investor’s account as
of the first day of the applicable month. The Management Fee will be prorated for any period that is less
than a full month and will be adjusted for subscriptions. For the Pura Vida Funds, the Adviser instructs
the Pura Vida Funds’ administrator to deduct the Management Fee from the relevant Pura Vida Fund’s
account.

In addition, the Clients are subject to carried interest or incentive allocation (collectively, the “Performance
Fee”) as set forth in each Client’s Governing Documents and is equal to a specified percentage of all
income, gains, and losses derived from portfolio investments. Either the Adviser or the general partner of
the Pura Vida Funds (and/or a designee thereof) is paid or allocated the Performance Fee.

In addition, the Clients may be subject to other expenses, such as legal, administration, accounting,
auditing, insurance, proxy voting services and other professional expenses, investment expenses such as
commissions, lobbying, research fees and expenses (including research-related travel); interest on margin
accounts and other indebtedness; borrowing charges on securities sold short; custodial fees, bank service
fees and other expenses related to the purchase, sale or transmittal of Client assets (including designated
investments). It is important that each investor who is considering an investment in a Client review the
Governing Documents applicable to that Client for a detailed description of the fees and expenses
applicable to such investment. Investors should review carefully Item 12, which discusses conflicts of
interest related to brokerage practices.

The Adviser, in its sole discretion, may waive or reduce the Management Fee and/or the Performance Fee
for investors including those that are members, employees or affiliates of the Adviser, relatives of such
persons, and/or for certain strategic investors.
Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure]
Item 7. Types of Clients

As described in Item 4, the Adviser’s clients are the Pura Vida Funds and Managed Accounts. Any initial
and additional subscription minimums for investors in Pura Vida Funds are disclosed in each Pura Vida
Fund’s Governing Documents.
CIK Period
0001590144
Sector Form 13F Holdings Value ($B)
Oncocyte Corp 0.0
Beta Bionics Inc 0.0
Establishment Labs Holdings Inc 0.0
Caris Life Sciences Inc 0.0
InspireMD Inc 0.0
Natera Inc 0.0
Nvidia Corp 0.0
J P Morgan Chase & Co 0.0
Microsoft Corp 0.0
Metagenomi Inc 0.0
Alphabet Inc 0.0
Outset Medical Inc 0.0
Analog Devices Inc 0.0
Apple Inc 0.0
ASML Holding NV 0.0
Linde PLC 0.0
Amazon Com Inc 0.0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prev | Page 1 | Next
Type Form D Funds Date Sold AUM
PE Pura Vida X Fund LP [2022-03-30] 17.5 M 30.2 M
Filed 2021-07-02 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
HF Pura Vida Pro Special Opportunity Master Fund Ltd [2020-03-25] 55.9 M 1.9 M
Filed 2024-11-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
PE Pura Vida Private Equity Fund LP [2016-03-14] 1.6 M 18.9 M
Offered $1,610,000 · Filed 2016-01-05 (D) · Exemption 506(b) · Duration One year or less · Revenue Decline to Disclose
PE Pura Vida SPV I LLC [2014-10-28] 5.8 M 14.1 M
Filed 2020-06-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Pura Vida Master Fund Ltd [2013-01-24] 257.6 M 20.4 M
Filed 2024-11-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 10 52.5
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 2 39.0
Total 12 91.5
By Discretionary
Discretionary 12 91.5
Non-Discretionary 0 0.0
Total 12 91.5
By Non-United States Persons
Non-United States Persons 20.4
United States Persons 71.1
Total 12 91.5
Form D Directors Role # Filings # Firms 2011 - 2026
Pura Vida Investments LLC Executive Officer 6 2
Pura Vida Funds Group GP LLC Executive Officer 5 2
Efrem Kamen Executive Officer 3 2
Pura Vida Pro LLC Executive Officer 1 1
Shayne Sowers Executive Officer 1 1
Narayan Krishnan Executive Officer 1 1
Pura Vida Pro GP LLC Executive Officer 1 1
Thomas Sowers Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001590144]
3 [0001590144]
4 [0001590144]
5 [0001590144]
SC 13D [0001590144]
SC 13G [0001590144]
Form 13D/13G Filer Form 13D/13G Subject Filed
Pura Vida Investments LLC Sonendo Inc [2024-11-14]
Pura Vida Investments LLC Oncocyte Corp [2024-11-14]
Pura Vida Investments LLC Cutera Inc [2023-04-13]
Pura Vida Investments LLC ICAD Inc [2023-03-15]
Pura Vida Investments LLC Oncocyte Corp [2023-02-14]
Pura Vida Investments LLC Quotient Ltd [2023-02-14]
Pura Vida Investments LLC APYX Medical Corp [2022-11-23]
Pura Vida Investments LLC Sonendo Inc [2022-11-22]
Pura Vida Investments LLC NanoString Technologies Inc [2022-11-09]
Pura Vida Investments LLC LYRA Therapeutics Inc [2022-11-08]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI549300D8Z5XG6F8J3C44
Form 3/4/5 Subject 2011 - 2026
Pura Vida Investments LLC
Oncocyte Corp
Kamen Efrem
Pura Vida Master Fund LTD
MedMen Enterprises Inc
Stryve Foods Inc
Greenlane Holdings Inc
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Oncocyte Corp OCX
Common Stock
2023-04-05 Buy 663,000 $0.30 198,900
Oncocyte Corp OCX
Common Stock
2023-03-06 Other 3,890,111
Oncocyte Corp OCX
Common Stock
2022-06-24 Sell 10,964 $1.05 11,512
Oncocyte Corp OCX
Common Stock
2022-06-24 Sell 12,517 $1.05 13,143
Oncocyte Corp OCX
Common Stock
2022-06-24 Sell 40,464 $1.03 41,678
Oncocyte Corp OCX
Common Stock
2022-06-24 Sell 35,441 $1.03 36,504
Oncocyte Corp OCX
Common Stock
2022-04-14 Buy 767,952 $1.33 1,021,376
Oncocyte Corp OCX
Common Stock
2022-04-14 Buy 1,665,898 $1.33 2,215,644
Oncocyte Corp OCX
Common Stock
2022-04-14 Buy 30,790 $1.23 37,872
Oncocyte Corp OCX
Common Stock
2022-04-14 Buy 1,916,419 $1.33 2,548,837
Oncocyte Corp OCX
Common Stock
2022-04-14 Buy 57,630 $1.26 72,614
Oncocyte Corp OCX
Common Stock
2022-04-14 Buy 19,210 $1.23 23,628
Oncocyte Corp OCX
Common Stock
2022-04-14 Buy 92,370 $1.26 116,386
Oncocyte Corp OCX
Warrant to purchase common stock · derivative
2022-04-14 Buy 690,719
Oncocyte Corp OCX
Warrant to purchase common stock · derivative
2022-04-14 Buy 383,976
Oncocyte Corp OCX
Warrant to purchase common stock · derivative
2022-04-14 Buy 832,949
Oncocyte Corp OCX
Warrant to purchase common stock · derivative
2022-04-14 Buy 958,209
Oncocyte Corp OCX
Common Stock
2022-04-14 Buy 1,381,438 $1.33 1,837,313
Stryve Foods Inc SNAX
Class A Common Stock
2021-09-15 Sell 800,000
Stryve Foods Inc SNAX
Prepaid Common Stock Purchase Warrant (right to buy) · derivative
2021-09-15 Buy 800,000
showing 20 of 92 most recent transactions
Comparable Firms State AUM
Ridgeline Productions LLC
NY 115.4 M
Islet Management LP
NY 108.8 M
Kalamata Asset Management LLC
MD 106.8 M
Stonebridge Partners LLC
NY 99.4 M
Arex Capital Management LP
NY 99.4 M
S Muoio & Co LLC
NY 95.1 M
Oxford Gate Management LLC
CT 90.9 M
Seaport Global Asset Management LLC
NY 80.0 M
Shoreline Capital Management Ltd
75.9 M
Abry Partners LLC
MA 69.3 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com